NCT03965728 - Study to Investigate Safety, Tolerability, Pharmacokinetics, and Drug-drug Interaction of Multiple Oral Doses of BAY1830839 in Healthy Male Participants | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 5, 2019

Primary Completion Date

January 21, 2022

Study Completion Date

May 11, 2022

Conditions

Healthy Volunteers

Interventions

DRUG

BAY1830839

Tablet, oral.

DRUG

Placebo

Tablet, oral.

DRUG

Midazolam

For all dose steps. Oral. Two single doses. One dose administered during pre-dose in Period 1 and the second dose administered on the last day of treatment with BAY1830839 or placebo in Period 2

DRUG

Methotrexate

Only for Dose 3 step. Tablet, oral. Two single doses. One dose administered during pre-dose in Period 1 and the second dose administered on the last day of treatment with BAY1830839 or placebo in Period 2.

Trial Locations (1)

10117

Charité Research Organisation GmbH, Berlin